Paliperidone palmitate
http://dbpedia.org/resource/Paliperidone_palmitate an entity of type: Thing
Paliperidone palmitate (PP), sold under the brand name Invega Sustenna among others, is an atypical antipsychotic which is used in the treatment of schizophrenia and schizoaffective disorder. It is an antipsychotic ester – specifically the palmitate ester of paliperidone – and acts as a long-lasting form of paliperidone. Paliperidone palmitate is formulated as an aqueous suspension and is administered by intramuscular injection into deltoid or gluteal muscle once every 1 or 3 months depending on the formulation. A formulation for injection once every 6 months is also pending regulatory approval as of September 2021.
rdf:langString
rdf:langString
Paliperidone palmitate
xsd:integer
19325299
xsd:integer
1118761740
xsd:integer
39
xsd:integer
199739
xsd:integer
83807
xsd:integer
2107360
xsd:integer
8028457
rdf:langString
DB01267
xsd:integer
1
xsd:integer
57
rdf:langString
[3-[2-[4-piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl] hexadecanoate
rdf:langString
D05340
rdf:langString
Rx-only
rdf:langString
Rx-only
rdf:langString
a607005
xsd:integer
4
xsd:integer
4
xsd:integer
9852746
rdf:langString
CCCCCCCCCCCCCCCCOC1CCCN2C1=NCC
xsd:integer
1
rdf:langString
VOMKSBFLAZZBOW-UHFFFAOYSA-N
rdf:langString
PP; PP1M; PP3M; PP6M; JNS-010; RO-92670; RO92670
rdf:langString
background:#ccccff
rdf:langString
Invega Hayfera, Invega Sustenna, Invega Trinza, others
rdf:langString
R8P8USM8FR
xsd:integer
250
rdf:langString
Paliperidone palmitate (PP), sold under the brand name Invega Sustenna among others, is an atypical antipsychotic which is used in the treatment of schizophrenia and schizoaffective disorder. It is an antipsychotic ester – specifically the palmitate ester of paliperidone – and acts as a long-lasting form of paliperidone. Paliperidone palmitate is formulated as an aqueous suspension and is administered by intramuscular injection into deltoid or gluteal muscle once every 1 or 3 months depending on the formulation. A formulation for injection once every 6 months is also pending regulatory approval as of September 2021. With the once-monthly formulation of paliperidone palmitate, the time to peak is 13 days and the elimination half-life is 25 to 49 days, and with the 3-month formulation, the time to peak is 30 to 33 days and the half-life is 84 to 95 days via deltoid muscle and 118 to 139 days gluteally. The peak-to-trough ratio of paliperidone palmitate at steady state ranges from 1.56 to 1.70 with the 1- and 3-month formulations. The 3-month formulation of paliperidone palmitate has larger crystal sizes than the 1-month formulation and this allows for its longer duration. No pharmacokinetic data for the 6-month formulation has been released as of January 2021.
rdf:langString
Paliperidone_palmitate
xsd:nonNegativeInteger
8388
rdf:langString
Invega Hayfera, Invega Sustenna, Invega Trinza, others
xsd:string
199739-10-1
xsd:string
83807
xsd:string
2107360
xsd:string
DB01267
xsd:string
R8P8USM8FR
xsd:string
D05340
xsd:string
a607005
xsd:string
9852746